Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy

Blood Cancer J. 2022 Sep 6;12(9):130. doi: 10.1038/s41408-022-00725-2.

Authors

Jarrod Longcor¹, Natalie Callander², Kate Oliver³, Asher Chanan-Khan^{4

5}, Sikander Ailawadhi^{4

5}

Affiliations

¹ Cellectar Biosciences, Inc., Florham Park, NJ, USA. [email protected].
² University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
³ Cellectar Biosciences, Inc., Florham Park, NJ, USA.
⁴ Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA.
⁵ Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

B-Cell Maturation Antigen
Humans
Immunotherapy
Immunotherapy, Adoptive
Iodine Radioisotopes
Multiple Myeloma* / therapy

Substances

B-Cell Maturation Antigen
Iodine Radioisotopes
Iodine-131

Grants and funding

HHSN261201500071C/CA/NCI NIH HHS/United States